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ABSTRACT: Conjugated linoleic acid (CLA) has been demon-
strated to reduce body fat in animals. However, the mechanism
by which this reduction occurs is unknown. Leptin may medi-
ate the effect of CLA to decrease body fat. We assessed the ef-
fects of 64 d of CLA supplementation (3 g/d) on circulating lep-
tin, insulin, glucose, and lactate concentrations in healthy
women. Appetite was assessed as a physiological correlate of
changes in circulating leptin levels. Analysis of plasma leptin
concentrations adjusted for adiposity by using fat mass as a co-
variate showed that CLA supplementation significantly de-
creased circulating leptin concentrations in the absence of any
changes of fat mass. Mean leptin levels decreased over the first
7 wk and then returned to baseline levels over the last 2 wk of
the study in the CLA-treated group. Appetite parameters mea-
sured at around the time when the greatest decreases in leptin
levels were observed showed no significant differences between
supplementation and baseline determinations in the CLA-sup-
plemented group or between the CLA and placebo-supple-
mented groups. There was a nonsignificant trend for mean in-
sulin levels to increase toward the end of the supplementation
period in CLA-treated subjects. CLA did not affect plasma glu-
cose and lactate over the treatment period. Thus, 64 d of CLA
supplementation in women produced a transient decrease in
leptin levels but did not alter appetite. CLA did not affect these
parameters in a manner that promoted decreases of adiposity.
Paper no. L8438 in Lipids 35, 783–788 (July 2000).
Conjugated linoleic acid (CLA) is the generic name for a
group of positional and geometric conjugated dienoic isomers
of linoleic acid. CLA has received considerable attention for
its anticarcinogenic (1) and antiatherogenic activities (2,3).
More recently CLA has been demonstrated to reduce body fat
in mice (4–6) and lower glucose and insulin levels in geneti-
cally obese Zucker fatty (fa/fa) rats (7). However, CLA has
also been shown to increase plasma insulin levels in mice (4).
Because CLA supplementation is being considered for the
treatment and prevention of obesity and diabetes, it would be
useful to determine the effects of CLA on plasma insulin and
glucose levels in humans.
The mechanism by which CLA exerts its effects on body
composition is unknown. In vitro studies suggest that CLA
reduces body fat by acting directly on adipocytes to enhance
lipolysis and decrease lipoprotein lipase activity (5). How-
ever, it is also possible that CLA mediates reductions of body
fat through leptin, the ob gene product that regulates adipos-
ity through decreases of food intake and increases in meta-
bolic rate (8–11). Leptin has also been shown to directly stim-
ulate lipolysis in adipose tissue explants (12) and cultured
adipocytes (13,14). CLA has been shown to decrease food in-
take and increase metabolic rate to varying degrees in mice
(5,6,15). Thus, increases of plasma leptin concentrations
could indeed mediate the effect of CLA to reduce body fat. 
In this study, we sought to assess the effects of 9 wk of
CLA supplementation on circulating leptin levels in healthy
women. Because a number of studies indicate that insulin (16)
and insulin-mediated glucose metabolism (17) regulate leptin
production by adipose tissue as well as changes of circulating
leptin concentrations in response to energy intake (18–20)
and energy restriction (21,22), plasma insulin and glucose
concentrations were measured throughout the study. Appetite
was assessed as physiological correlate of changes in leptin
production. 
MATERIALS AND METHODS
Subjects and study design. Twenty-four women were re-
cruited for this study, and 17 women completed it. Potential
subjects completed a medical and physical examination, stan-
dard blood test, diet history, assessment of eating behavior to
rule out eating disorders, and a urine test for pregnancy. Sub-
jects selected for inclusion were all healthy, nonsmoking
women between the ages of 20 and 41 yr of age and with nor-
mal menstrual cycles. Subjects lived in the metabolic suite at
the Western Human Nutrition Research Center, University of
California (Davis, CA) 24 hr/d, 7 d/wk for the entire study,
which consisted of a 30-d stabilization period followed by a
64-d intervention period. At the end of the baseline period,
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10 subjects were randomly assigned to receive a CLA supple-
ment and 7 were assigned to receive a sunflower oil placebo.
The subjects and technical/support staff were blinded as to
the treatment assignments. 
At the beginning of the intervention period, 3 g/d (approx-
imately 1% of daily energy intake) of CLA was given in the
form of a treatment capsule from Pharmanutrients, Inc. (Lake
Bluff, IL) until the study was completed. Of the fatty acids in
the capsules 65% were CLA isomers, and gas chromatogra-
phy showed that the isomer composition was 22.6% trans-10,
cis-12; 23.6% cis-11,trans-13; 17.6% cis-9,trans-11; 16.6%
trans-8,cis-10; 7.7% trans-9,trans-11 and trans-10,trans-12;
and 11.9% other isomers. Placebo capsules made from sun-
flower oil contained 72.6% linoleic acid and no detectable
CLA; they were taken during the baseline period by all sub-
jects and during the intervention period by the control group.
The CLA and placebo capsules were identical in appearance. 
Both baseline and intervention diets met the Recommended
Daily Allowance for all known nutrients and were matched
with respect to energy as a percentage of calories from carbo-
hydrate, protein, and fat (55, 15, and 30%, respectively). The
caloric intake of each subject was estimated with the Harris-
Benedict equation and intake adjusted during the baseline pe-
riod to maintain body weight. The diet was provided as a rotat-
ing 5-d menu. Four meals were served daily. Meal times were
set at 8:30–9:00 A.M. for breakfast, 12:00–12:30 P.M. for lunch,
5:00–5:30 P.M. for dinner, and 7:00–7:30 P.M. for evening
snack. Subjects walked 2 mi twice daily; this and other activi-
ties were controlled carefully throughout the study. For all sub-
jects, blood was collected between 7:00–8:00 A.M. by antecu-
bital venipuncture after an overnight fast. Weight was assessed
daily before breakfast. All subjects gave their informed con-
sent. The study protocol was approved by the Human Subjects
Committees of the U.S. Department of Agriculture and the
University of California, Davis.
Appetite assessment. Appetite was assessed with the use
of visual analog scales. Subjects marked their answers on a
line displayed on the screen of a handheld computer (Palm
Pilot©). Feelings of hunger, fullness, and prospective con-
sumption (an assessment of the amount of food that could be
eaten) were reported hourly from 7:00 A.M. to 10:00 P.M.; the
area under the curve (AUC) was then calculated from the re-
sponses. Baseline appetite was assessed during the third week
of the baseline period, and treatment effects were measured
after 6 wk of intervention. Appetite measurements were per-
formed every other day for three replicates. The same menu
days of the baseline test were chosen as the measurement
days for the treatment period. 
Assays. Leptin concentrations in the plasma were deter-
mined with radioimmunoassay kits (Linco Research, St. Louis,
MO) as previously described (23). For human leptin, the intra-
and interassay coefficients were <8%. Plasma insulin concen-
trations were measured with a specific radioimmunoassay for
human insulin (ICN Diagnostic Div., ICN, Costa Mesa, CA)
according to the method of Yalow and Berson with minor mod-
ifications (24). Plasma glucose and lactate concentrations were
measured with a YSI 2300 StatPlus Glucometer (Yellow
Springs Instruments, Yellow Springs, OH). 
Data analysis. A linear model with time taken as a re-
peated measure was used to determine the effects of CLA on
appetite, plasma leptin, glucose, and lactate levels. The leptin
data were also analyzed after adjustment for body fat mass by
including body fat mass as a covariate in the model. The fat
mass values utilized were obtained as previously described
(25). These analyses were performed using the Statistical
Analysis System (SAS Institute, Inc., Cary, NC). Owing to
the wide variation in fasting insulin levels between subjects,
the insulin data were analyzed as the percentage change in in-
sulin from baseline levels for each subject. To determine the
effect of CLA on plasma insulin levels, the AUC (trapezium
rule) for the percentage change in insulin levels was calcu-
lated for each subject, and the mean AUC for the CLA and
placebo-supplemented groups were compared by a two sam-
ple t-test. Data are expressed as the mean ± SEM. The proba-
bility level for significance was set at P < 0.05, and a Bonfer-
roni adjustment applied to multiple comparisons where ap-
propriate. 
RESULTS
Effect of CLA on plasma leptin concentrations. Leptin levels
initially decreased and then returned to baseline levels in
CLA-treated subjects (Table 1, Fig. 1A). Analysis of plasma
leptin concentrations adjusted for adiposity by using fat mass
as a covariate showed that CLA supplementation significantly
decreased leptin levels (P = 0.05). Adiposity-adjusted leptin
levels tended to be low at 33 d and were decreased signifi-
cantly after 49 d in the CLA-supplemented group compared
to the placebo-supplemented group and baseline values (P =
0.02 and P = 0.04, respectively). From the low point at 49 d,
leptin concentrations in the CLA-treated group increased until
they returned to near-baseline levels by the end of the study.
After 57 d of supplementation, mean leptin levels in the CLA-
treated group, although lower, were not significantly different
from leptin levels in the placebo-treated group or from base-
line values (P = 0.12 and P = 0.17, respectively). Since
plasma leptin levels were not assessed between 33 and 49 d,
the maximal effect of CLA on plasma leptin levels could have
occurred during this time period. Changes of absolute and
plasma leptin concentrations normalized as the ratio of leptin
to fat mass or percentage fat mass in the CLA-supplemented
group (Table 1) were similar to changes of adiposity-adjusted
leptin concentrations. For example, mean absolute leptin lev-
els were at their lowest point after 49 d of CLA supplementa-
tion. Over the entire supplementation period, CLA tended to
decrease absolute and normalized plasma concentrations of
leptin (P = 0.10). All of the observed changes in leptin con-
centrations occurred in the absence of detectable changes of
fat mass (25) and body mass index (BMI) (Table 1). 
Effect of CLA on plasma insulin, glucose, and lactate con-
centrations. There was a nonsignificant trend for mean
plasma insulin levels to increase in CLA-treated subjects
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(Table 1 and Fig. 1B). The mean percentage change in insulin
levels from baseline increased over the last 2 wk of the study
in the CLA-supplemented group; this change coincided with
the increase in leptin from the low point in leptin concentra-
tions at 49 d (Figs. 1A and 1B). The mean AUC for the per-
centage change in insulin levels from baseline was 1039 ±
708 and −208 ± 895 for the CLA and placebo-supplemented
groups, respectively. Although the difference in the mean
AUC between the two groups was not significant (P = 0.17),
it is possible that significance would have been attained with
a larger sample size. CLA did not have any effect on plasma
glucose (P = 0.524) and lactate concentrations (P = 0.845)
(Table 1).
Effect of CLA on appetite. The AUC ratings during the
baseline and supplementation periods for hunger, fullness,
and prospective consumption showed that none of the three
appetite measures was significantly affected by CLA treat-
ment (Table 2). In addition, an approximately equal number
of subjects had increased or decreased hunger, fullness, or
prospective consumption in the CLA and placebo-supple-
mented groups (data not shown).
DISCUSSION
The present study is the first to examine the effects of CLA
supplementation on circulating leptin levels in humans. CLA
supplementation significantly decreased leptin concentrations
without any detectable changes of body fat mass. After 7 wk
of treatment, in the CLA-supplemented group, circulating
leptin concentrations were at their lowest point. Thereafter,
over the last 2 wk of intervention, leptin concentrations rose
to pretreatment levels. These data are consistent with a recent
study, which showed that plasma leptin concentrations tended
to decrease in CLA-treated mice maintained on a high-fat diet
(4). In mice fed a diet of 1% CLA by weight, plasma leptin
levels were significantly decreased after 6 wk of treatment but
did not differ from controls after 8 wk. However, since the
1% CLA diet decreased several different fat depots by greater
EFFECTS OF CLA ON LEPTIN AND APPETITE 785
Lipids, Vol. 35, no. 7 (2000)
TABLE 1
Mean BMI; Absolute and Normalized Plasma Leptin, Insulin, Glucose, and Lactate Concentrations;
and Mean Change During 63 d of Treatment with Placebo or CLAa
Baseline 33-d Treatment 49-d Treatment 57-d Treatment 63-d Treatment
BMI (kg/m2)
Placebo 22.2 ± 1.3 22.1 ± 1.2 22.6 ± 1.6 22.1 ± 1.4 22.2 ± 1.4
∆ −0.05 ± 0.07 0.0 ± 0.1 −0.1 ± 0.2 0.1 ± 0.2
CLA 23.2 ± 0.5 23.3 ± 0.5 23.0 ± 0.5 23.1 ± 0.5 23.1 ± 0.5
∆ −0.05 ± 0.07 −0.2 ± 0.1 −0.1 ± 0.1 −0.1 ± 0.1
Leptin (ng/mL)
Placebo 16.7 ± 4.3 15.5 ± 5.0 16.8 ± 5.9 16.2 ± 5.0 15.7 ± 4.6
∆ −0.2 ± 0.8 1.0 ± 1.6 −0.6 ± 1.6 −1.0 ± 1.8
CLA 16.0 ± 2.5 13.3 ± 2.4 12.9 ± 2.3a,b 13.8 ± 2.2 15.1 ± 3.6
∆ −2.8 ± 0.7 −3.2 ± 0.6 −2.3 ± 1.1 0.3 ± 1.8
Leptin/fat mass (ng/mL/kg)
Placebo 0.79 ± 0.12 0.73 ± 0.11 0.76 ± 0.15 0.76 ± 0.09 0.76 ± 0.11
∆ 0.02 ± 0.02 0.05 ± 0.08 −0.03 ± 0.08 −0.03 ± 0.11
CLA 0.83 ± 0.10 0.67 ± 0.07a 0.66 ± 0.08a 0.68 ± 0.07 0.78 ± 0.15
∆ −0.16 ± 0.07 −0.17 ± 0.04 −0.14 ± 0.07 0.02 ± 0.08
Leptin/% fat mass (ng/mL)
Placebo 0.51 ± 0.10 0.51 ± 0.10 0.51 ± 0.13 0.50 ± 0.10 0.50 ± 0.10
∆ 0.03 ± 0.02 0.03 ± 0.05 −0.01 ± 0.05 −0.01 ± 0.07
CLA 0.52 ± 0.07 0.43 ± 0.06 0.41 ± 0.06b 0.43 ± 0.05 0.52 ± 0.10
∆ −0.09 ± 0.04 −0.10 ± 0.03 −0.09 ± 0.04 0.03 ± 0.05
Insulin (pmoles/L)
Placebo 64.6 ± 13.2 55.6 ± 8.3 71.5 ± 13.2 54.2 ± 9.0 70.1 ± 13.2
∆ −14.6 ± 6.9 1.4 ± 4.2 −10.4 ± 6.9 5.6 ± 6.3
CLA 54.9 ± 10.4 50.7 ± 5.6 65.3 ± 13.2 60.4 ± 8.3 65.3 ± 6.3
∆ −3.5 ± 6.3 10.4 ± 6.3 6.3 ± 8.3 10.4 ± 10.4
Glucose (mmoles/L)
Placebo 4.11 ± 0.17 4.05 ± 0.21 4.25 ± 0.24 3.92 ± 0.29 4.08 ± 0.22
∆ −0.10 ± 0.17 0.10 ± 0.19 −0.18 ± 0.23 −0.02 ± 0.17
CLA 4.04 ± 0.09 4.04 ± 0.18 4.01 ± 0.16 4.11 ± 0.19 4.1 ± 0.23
∆ −0.01 ± 0.11 −0.03 ± 0.11 0.07 ± 0.14 0.06 ± 0.18
Lactate (mmoles/L)
Placebo 2.25 ± 0.29 2.11 ± 0.40 3.06 ± 0.59 2.36 ± 0.17 2.43 ± 0.21
∆ −0.14 ± 0.46 0.62 ± 0.54 0.11 ± 0.33 0.18 ± 0.22
CLA 2.39 ± 0.34 2.68 ± 0.34 2.89 ± 0.29 2.78 ± 0.39 2.33 ± 0.23
∆ 0.29 ± 0.37 0.49 ± 0.42 0.39 ± 0.62 −0.06 ± 0.48
aMean ± SEM; n = 7 for placebo and n = 10 for CLA. Treatment change (∆) values represent mean change from baseline;
BMI, body mass index; CLA, conjugated linoleic acid. aP < 0.05 vs. baseline. bP < 0.05 vs. placebo. 
than 50% after 6 wk of treatment, it is possible that the de-
creased leptin levels resulted from a reduction of body fat in
the mice. However, by the end of that study, while overall fat
mass decreased nearly 43%, leptin levels no longer differed
from control levels. Thus, it is possible, like the present study,
that CLA had effects on leptin levels that were independent
of changes in fat mass.
To assess whether CLA-mediated changes in leptin levels
were related to changes in appetite, self-ratings of hunger,
fullness, and prospective consumption were determined. We
have previously reported that in energy-restricted human fe-
males, subjects with lower leptin concentrations and greater
percentage decreases in circulating leptin reported greater
feelings of hunger, desire to eat, and prospective consump-
tion than those with higher leptin concentrations and smaller
decreases in leptin (26). In the present study, although ap-
petite parameters were measured at around the time when the
greatest decreases in leptin levels were observed, there were
no significant differences between supplementation and base-
line determinations in the CLA-supplemented group or be-
tween the CLA and placebo-supplemented groups. It is possi-
ble that there were undetected changes in appetite that were
related to the decrease in leptin levels; the subjective assess-
ment of appetite may be a gross measure that does not pick
up subtle changes in appetite. However, in the present study,
in contrast to the previous one, the subjects were on a mainte-
nance rather than an energy-restricted diet. Therefore, the de-
creases of circulating leptin levels were much more modest
(~20%) in the present study than during energy restriction
(~50–70%). It is also possible that other physiological changes,
in addition to decreases in leptin concentration, are required to
mediate changes of appetite. Although changes in leptin levels
have been shown to modulate energy expenditure (8–11), it
was also not affected in the present study by CLA treatment
despite the changes in circulating leptin concentrations (25).
Thus, the physiological significance of the changes that were
observed in circulating leptin levels are not clear.
Plasma insulin levels tended to increase in CLA-treated
subjects over the last 2 wk of the supplementation period.
This change coincided with the increase in leptin concentra-
tions from their low point at 49 d. A recent study showed that
changes in plasma leptin correlate with changes of fasting
plasma insulin independent of changes of BMI or percentage
body fat (27). It was also demonstrated that insulin adminis-
tration, at doses producing increments of insulin within the
physiological range, increases circulating leptin concentra-
tions in humans (28, 29). Thus, it is possible that the increase
in insulin levels mediated the return of leptin concentrations
to baseline levels. A trend for circulating insulin levels to in-
crease with CLA supplementation was recently demonstrated
in rodents by DeLany and colleagues (4). They reported that
plasma insulin levels of CLA-fed mice tended to increase
over the treatment period but did not reach significance until
after 8 wk. Similar to the present study, this change in insulin
levels occurred about 1 wk following the greatest difference
in leptin levels between CLA-treated and control mice, and it
also coincided with the increase in leptin to control levels.
Thus, for both studies, it is possible that increases in insulin
levels influenced circulating leptin concentrations. 
The increase in insulin levels may have been part of a
homeostatic response to counter the effect of CLA to decrease
leptin. There are other possible explanations for the transient
effect of CLA on circulating leptin concentrations. Initially,
as suggested by a recent in vitro study (7), CLA could have
acted as a ligand that activated peroxisome proliferator-acti-
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FIG. 1. Percentage change in leptin (A) and insulin (B) concentrations
from baseline levels in conjugated linoleic acid (CLA) and placebo-sup-
plemented subjects.  Blood samples were collected after an overnight
fast at baseline and at days 33, 49, 57, and 63 of intervention. Leptin
and insulin concentrations were assessed by radioimmunoassay. Mean
± SEM; n = 7 for placebo and n = 10 for CLA. aP < 0.05 vs. baseline.
TABLE 2
Mean Ratings of Hunger, Fullness, and Prospective Consumptiona
After 6 wk
Baseline of treatment
Hunger (AUC as mm·h)
Placebo 486 ± 59 467 ± 50
CLA 508 ± 77 518 ± 64
Fullness (AUC as mm·h)
Placebo 798 ± 75
CLA 716 ± 56 727 ± 32
Prospective consumption (AUC as mm·h)
Placebo 514 ± 97 500 ± 72
CLA 531 ± 83 568 ± 61
aSummarized mean of area under the curve (AUC) ± SEM for 16 hourly in-
quiries throughout the day; n = 7 for placebo and n = 10 for CLA.
vated receptor-γ (PPAR-γ). In turn, activation of PPAR-γ has
been demonstrated to decrease leptin gene expression in ro-
dents (30) and an adipocyte cell line (31). An event that could
have occurred later during the intervention is demonstrated
by a study in which rats fed a 1% CLA diet incorporated the
cis-9,trans-11-isomer into membrane phospholipids of mam-
mary epithelial cells (1). The investigators suggested that the
incorporation of CLA into phospholipids could have various
effects on signal transducing pathways. It is conceivable that
altered signaling affected leptin production as CLA incorpo-
ration into adipocyte membranes increased. 
In summary, 64 d of CLA supplementation in women pro-
duced a transient decrease in leptin levels but did not alter ap-
petite or energy expenditure. These results are counter to what
would be expected if CLA were able to reduce body fat in hu-
mans as it does in animals.
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